<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744571</url>
  </required_header>
  <id_info>
    <org_study_id>DCB at CTO</org_study_id>
    <nct_id>NCT04744571</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions</brief_title>
  <official_title>Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of drug-coated balloon&#xD;
      angioplasty for the treatment of chronic total occlusions patients with chronic total&#xD;
      occlusion (CTO) lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruited CTO patients will be divided into two groups: those undergoing PCI of drug-coated&#xD;
      balloon (DCB group), and those undergoing PCI of drug eluting stent implantation (DES group).&#xD;
      The primary outcome assessed will be the late lumen loss evaluation at a 12-month of&#xD;
      follow-up appointment. Secondary outcomes include occurrence of major cardiac events (MACEs),&#xD;
      myocardial viability, operate success, quality of life changes which will be compared to a&#xD;
      baseline measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the difference in minimal lumen diameter (MLD) between two groups</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Intravascular ultrasound (IVUS) or optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the incidence of major adverse cardiac events（MACEs） between two groups</measure>
    <time_frame>12 months</time_frame>
    <description>all-cause mortality, cardiac death, a first or recurrent, non-fatal, acute myocardial infarction, target lesion revascularization (PCI or CABG), stroke, heart failure and cardiac rehospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of myocardial viability (late gadolinium enhancement, LGE) in the territory supplied by the CTO artery between two groups evaluated via cardiovascular magnetic resonance (CMR)</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial viability in the territory supplied by the CTO artery by comparison of late gadolinium enhancement between two groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of the incidence of adverse cardiac events between two groups in the perioperative period</measure>
    <time_frame>7 days before and after procedure</time_frame>
    <description>Outcome measures including acute coronary artery occlusion, acute vascular perforation, acute stent thrombosis, acute myocardial infarction, and cardiac death</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Occlusion</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Drug-Eluting Stents</condition>
  <arm_group>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Drug-Coated Balloon Angioplasty after revascularization of Chronic Total Occlusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DES group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with Drug eluting stents Angioplasty after revascularization of Chronic Total Occlusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor</intervention_name>
    <description>Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.</description>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_label>DES group</arm_group_label>
    <other_name>Optimal medical therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>coronary wires. or coronary balloons</intervention_name>
    <description>all species of coronary wires, or plain balloons</description>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_label>DES group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>drug-coated balloon</intervention_name>
    <description>Drug-coated balloon including all sizes and all brands</description>
    <arm_group_label>DCB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting stent</intervention_name>
    <description>Drug-eluting stent including all sizes and all brands</description>
    <arm_group_label>DES group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients between 18 and 80 years of age&#xD;
&#xD;
          -  Must comply all the evaluations and follow-up protocols&#xD;
&#xD;
          -  Clinical diagnosis of CTO detected using coronary angiography (at least one other&#xD;
             major vessel should have exhibited no less than 75% stenosis)&#xD;
&#xD;
          -  Patients should present with left ventricular ejection fraction (LVEF) above 35%&#xD;
             determined using transthoracic echocardiography&#xD;
&#xD;
          -  CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5 mm&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients have suffered from acute myocardial infarction within the previous 3 months&#xD;
&#xD;
          -  Lesion located in the left main artery (stenosis ≥50%)&#xD;
&#xD;
          -  Clinical diagnosis of rheumatic valvular disease&#xD;
&#xD;
          -  Clinical diagnosis of severe arrhythmia&#xD;
&#xD;
          -  With history of revascularization within the CTO artery&#xD;
&#xD;
          -  Lesions unsuitable for PCI&#xD;
&#xD;
          -  Severely abnormal hematopoietic systems, such as platelet counts &lt;100 x 109/L or &gt; 700&#xD;
             x 109/ L and white blood cell counts &lt; 3 x 109/L&#xD;
&#xD;
          -  Patients with active bleeding or bleeding tendencies (active ulcers, short-term&#xD;
             ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions,&#xD;
             recent craniocerebral trauma, and other bleeding or bleeding tendency)&#xD;
&#xD;
          -  Patients with severe coexisting condition including: severe renal function dysfunction&#xD;
             [Glomerular filtration rate (GFR) less than 60 ml/min • 1.73 m2), severe hepatic&#xD;
             dysfunction [glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase&#xD;
             (ALT) elevated more than three times that of the upper limit of the normal reference],&#xD;
             severe heart failure (NYHA classification III-IV), acute infectious diseases and&#xD;
             immune disorders, tumors, surgery within 3 months, a life expectancy less than 12&#xD;
             months, pregnancy or planning to become pregnant, history of allergy or adverse&#xD;
             reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material,&#xD;
             anticoagulant, or stents&#xD;
&#xD;
          -  Patients cannot tolerate dual antiplatelet treatment (DAPT)&#xD;
&#xD;
          -  Patients are unable to communicate due to cognitive impairment, auditory or visual&#xD;
             impairment&#xD;
&#xD;
          -  Patients are participating in another trial for medication or an apparatus and in&#xD;
             which the main endpoint has not been reached, or plan to participate in a clinical&#xD;
             trial within 12 months of the intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiantao song, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Xiantao Song, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Total Occlusion</keyword>
  <keyword>drug-coated balloon</keyword>
  <keyword>balloon angioplasty</keyword>
  <keyword>drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

